米氮平治疗大肠癌术后化疗相关焦虑抑郁的疗效观察

The Effect of Mirtazapine on Chemotherapy-related Anxiety and Depression in Patients with Colorectal Cancer After Surgery

[目的]评价米氮平对大肠癌术后化疗患者焦虑、抑郁的疗效及化疗不良反应的影响。[方法]根据汉密尔顿焦虑—抑郁量表筛选出56例大肠癌术后化疗后出现焦虑、抑郁的患者,随机分为米氮平组和对照组,观察8周后评定米氮平对化疗患者焦虑、抑郁的疗效及对化疗不良反应的影响。[结果]米氮平组在化疗后第2、4及8周的焦虑、抑郁量表评分均低于化疗前水平(P<0.05),且明显低于同期对照组(P<0.01)。米氮平组恶心呕吐、失眠等不良反应显著减轻(P<0.05),且米氮平不加重骨髓抑制、肝肾功能损害及神经毒性等化疗不良反应(P>0.05)。[结论]米氮平干预大肠癌术后化疗伴发焦虑、抑郁障碍患者疗效显著,可有效改善生活质量,减轻化疗引起的不良反应。

[Purpose] To investigate the effect of mirtazapine on chemotherapy-related anxiety,depression and chemotherapy side effects in patients with colorectal cancer after surgery.[Methods] Fiftysix colorectal cancer patients with chemotherapy-related anxiety and（or） depression screened by the Hamilton Depression Scale（HAMD） and Hamilton Anxiety Scale（HAMA） were randomly divided into mirtazapine group and control group.The influences of mirtazapine on chemotherapy-related anxiety,depression and chemotherapy side effects were observed.[Results] The HAMD and HAMA scores in mirtazapine group after 2,4 and 8 weeks of chemotherapy were significantly lower than those before chemotherapy（P 0.05）.[Conclusion] Mirtazapine can lighten the chemotherapy-related anxiety and depression,improve the quality of life and reduce the occurrence of chemotherapy side effects.